Scholar Rock's ISEMBYLD Wins FDA Approval As First Muscle-Targeted Therapy For SMA

(RTTNews) - Scholar Rock (SRRK) announced that the U.S. Food and Drug Administration approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SM